SUP - Alzheimer’s Disease and Alzheimer’s Disease-Related Dementias (AD/ADRD) Research Supplements to Promote Diversity in Health-Related Research


SUP - Alzheimer’s Disease and Alzheimer’s Disease-Related Dementias (AD/ADRD) Research Supplements to Promote Diversity in Health-Related Research

Notice Number: NOT-NS-19-003

Key Dates
Release Date:October 1, 2018

Related Announcements

Issued by
National Institute of Neurological Disorders and Stroke (NINDS)


This Notice encourages eligible NINDS awardees in the Alzheimer’s Disease and Alzheimer’s Disease-Related Dementias (AD/ADRD) research community to apply for administrative supplements in response to PA-18-906, "Research Supplements to Promote Diversity in Health-Related Research." The NIH has a strong interest in the diversity of the NIH-funded workforce (see NOT-OD-20-031 for details) and encourages institutions to diversify their student populations by enhancing the participation of individuals from groups that are underrepresented in the biomedical, clinical, behavioral, and social sciences. Goal 1 of The National Plan to Address Alzheimer’s Disease is to prevent and effectively treat AD/ADRD by 2015. This initiative addresses the critical need to increase the number of health professionals who are trained to meet the expanding demand for cognitive impairment and dementia diagnosis, care, and clinical research to meet Goal 1.

Program Directors/Principal Investigators (PD/PI) of active AD/ADRD research grants are thus encouraged to identify eligible individuals, including those from underrepresented groups, for support and mentorship under the auspices of this supplement opportunity. Individuals from the identified groups are eligible throughout the training continuum from high school to the faculty level. The activities proposed in the supplement application must fall within the scope and advance the objectives of the parent grant, and also support the research training and professional development of the supplement candidate. PIs must reference this Notice in the cover letter and application. For further guidance on submitting a responsive NINDS diversity supplement please visit this link: 

Diversity supplement awardees, as appropriate for the duration of their support and career stage, may request funds, in addition to the research costs specified in  PA-18-906 , to enable the supplement candidate to attend the AD/ADRD research summits in the Washington, DC area. This request for additional funds should be reasonable and well justified in the application. 

Applicants are strongly encouraged to consult with the Program Official for the parent grant or the contact listed below before submitting an application to confirm eligibility and to obtain technical assistance. Supplement requests under this Notice (and submitted to PA-18-906will undergo administrative evaluation by NINDS staff, but not a full peer review. Eligible AD/ADRD research awards can be identified by using NIH RePORTER or by contacting Dr. Jordan Gladman via email. For tracking, when a diversity supplement application responsive to this Notice is submitted please email Dr. Jordan Gladman and include the PD/PI name and grant number in the subject line of the email.

Applications will be considered according to the following schedule:

Application Due Date    Earliest Funding Decision
November 16, 2018 – February 15, 2019   March 2019
February 16, 2019 – May 15, 2019    June 2019
August 1, 2019 – November 15, 2019   December 2019
November 16, 2019 – February 15, 2020   March 2020
February 16, 2020 – May 15, 2020  June 2020



Please direct all inquiries to:

Rod Corriveau, Ph.D.
National Institute of Neurological Disorders and Stroke (NINDS) 
Telephone: 301-496-5680